AI-picked stocks now up 150%+; an 111% outperformance vs. the S&P 500
Nicole Negar Davarpanah, Chief Medical Officer of Cidara Therapeutics, Inc. (NASDAQ:CDTX), sold 474 shares of common stock on September 11, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The transaction comes as the company’s stock trades near its 52-week high of $69.36, having delivered an impressive 460% return over the past year, according to InvestingPro data. The shares were sold at weighted average prices ranging from $62.86 to $63.50, for a total transaction value of $29,796.
The sale was to cover tax withholding obligations related to the vesting and settlement of Restricted Stock Units (RSUs) and does not represent a discretionary transaction. Following the transaction, Davarpanah directly owns 31,418 shares of Cidara Therapeutics, representing a stake in the company’s $1.72 billion market capitalization. This includes 200 shares acquired through the company’s Employee Stock Purchase Plan on May 20, 2025. Analysts maintain a bullish outlook on CDTX, with price targets ranging from $66 to $115. For detailed valuation analysis and 11 additional key insights about CDTX, visit InvestingPro.
In other recent news, Cidara Therapeutics has seen notable developments. Guggenheim raised its price target for Cidara Therapeutics to $70, citing progress in FDA discussions and maintaining a Buy rating. The company has an end-of-Phase 2 meeting scheduled, with expectations of continuity from previous discussions. Citizens JMP also increased its price target for Cidara to $66, highlighting the potential of the company’s Cloudbreak technology and the development of CD388. Meanwhile, Sidera Therapeutics reported its second-quarter 2025 earnings, emphasizing progress in its product pipeline and strategic initiatives. Despite not generating revenue, Sidera maintains a strong financial position with over $500 million in cash, supported by a recent public offering. These developments reflect ongoing advancements and strategic progress in both companies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.